StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities researchers at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NYSE NBY opened at $0.58 on Friday. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The firm’s 50-day simple moving average is $0.66 and its 200 day simple moving average is $0.62. The stock has a market cap of $2.83 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.